Patient Characteristics and Treatment
DISEASE PROGRESSION, ADVERSE EVENTS, ADHESION, ONCOLOGY, DISEASE CHARACTERISTIC
In cohort Q2W-LD, 38 patients were screened for eligibility and 28 patients were enrolled and treated with tusamitamab ravtansine across four LD-DLs ranging from 120 to 170 mg/mBaseline demographics and disease characteristics by DL in cohorts Q2W-LD and Q3W (all-treated/safety population)Abbreviations: C1, cycle 1; CEA, carcinoembryonic antigen; CEACAM5, carcinoembryonic antigen-related cell adhesion molecule 5; ECOG PS, Eastern Cooperative Oncology Group performance status; Q2W, every 2 weeks; Q2W-LD, cohort receiving a loading dose at day 1, cycle 1, followed by a fixed dose every 2 weeks; Q3W, cohort receiving tusamitamab ravtansine every 3 weeks; Q3W, every 3 weeks; RECIST, Response Evaluation Criteria in Solid Tumours.

As of the date of publication, all patients in cohort Q2W-LD and in cohort Q3W had discontinued treatment. In cohort Q2W-LD, 26 patients discontinued treatment because of disease progression and 2 because of adverse events (AEs), and in cohort Q3W, 14 patients discontinued treatment because of disease progression and 1 because of AEs.The median ages of patients in cohorts Q2W-LD and Q3W were 59.5 and 59.0 years, respectively, and a majority were male (67.9% and 53.3%, respectively; In cohort Q2W-LD, a total of 128 cycles were administered across all DLs (At the time of study cutoff, in cohort Q3W, a total of 39 cycles were administered across all DLs (